KBC Group NV Sells 41,585 Shares of BioMarin Pharmaceutical Inc. $BMRN

Posted by Brian Himes on Jul 23rd, 2026

KBC Group NV trimmed its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 24.6% in the 1st quarter, HoldingsChannel reports. The firm owned 127,194 shares of the biotechnology company’s stock after selling 41,585 shares during the period. KBC Group NV’s holdings in BioMarin Pharmaceutical were worth $7,185,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors also recently bought and sold shares of the company. Activest Wealth Management bought a new position in shares of BioMarin Pharmaceutical in the fourth quarter worth about $26,000. CIBC Private Wealth Group LLC grew its stake in shares of BioMarin Pharmaceutical by 38.2% during the 4th quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 179 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in BioMarin Pharmaceutical in the 3rd quarter worth approximately $40,000. V Square Quantitative Management LLC purchased a new stake in BioMarin Pharmaceutical in the 4th quarter worth approximately $45,000. Finally, Parallel Advisors LLC raised its stake in BioMarin Pharmaceutical by 62.2% during the 3rd quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 295 shares during the period. 98.71% of the stock is owned by institutional investors.

BioMarin Pharmaceutical Price Performance

BioMarin Pharmaceutical stock opened at $58.40 on Thursday. BioMarin Pharmaceutical Inc. has a 52-week low of $49.26 and a 52-week high of $66.28. The company has a quick ratio of 4.20, a current ratio of 5.81 and a debt-to-equity ratio of 0.23. The firm’s fifty day moving average is $56.27 and its 200 day moving average is $56.82. The company has a market cap of $11.29 billion, a price-to-earnings ratio of 42.63, a PEG ratio of 0.45 and a beta of 0.24.

Insider Buying and Selling at BioMarin Pharmaceutical

In other news, EVP Gregory R. Friberg sold 3,281 shares of the business’s stock in a transaction dated Thursday, May 7th. The shares were sold at an average price of $53.85, for a total value of $176,681.85. Following the sale, the executive vice president directly owned 51,818 shares in the company, valued at $2,790,399.30. The trade was a 5.95% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 0.68% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of analysts have recently issued reports on BMRN shares. HC Wainwright reissued a “neutral” rating on shares of BioMarin Pharmaceutical in a research note on Tuesday, July 14th. Wall Street Zen lowered BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research note on Saturday, June 6th. Bank of America decreased their price target on BioMarin Pharmaceutical from $85.00 to $80.00 and set a “buy” rating on the stock in a report on Tuesday, May 19th. Truist Financial upgraded BioMarin Pharmaceutical to a “strong-buy” rating in a research report on Wednesday, March 25th. Finally, Weiss Ratings raised BioMarin Pharmaceutical from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Friday, June 26th. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and eight have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $88.26.

View Our Latest Stock Analysis on BioMarin Pharmaceutical

BioMarin Pharmaceutical Profile

(Free Report)

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.